4 results about "Acidosis" patented technology

To provide an ATP production promoter useful for preventing or treating diseases associated with decreased ATP production, particularly renal impairment. [Solution] The present invention comprises an ATP production promoter containing a component having URAT1 inhibitory activity. Preferably, the component having URAT1 inhibitory activity is at least one selected from the group consisting of benzbromarone, probenecid, dotinurad, recinurad, and berinurad. The present invention is expected to be useful as a preventive and therapeutic agent for diseases of decreased ATP production, and is particularly useful as a therapeutic and / or preventive agent for nephrotic syndrome, chronic glomerulonephritis, chronic tubulointerstitial nephritis, chronic pyelonephritis, amyloid kidney, familial juvenile hyperuricemia nephropathy, autosomal dominant tubulointerstitial kidney disease, nephronoplasia, renovascular hypertension, renal vein thrombosis, renal arteriovenous fistula, renal tubular acidosis, Gitelman syndrome, Bartter syndrome, Fanconi syndrome, Lowe syndrome, Alport syndrome, kidney and ureteral stones, and chronic renal failure.

The application discloses application of MANF in preparation of a medicine for treating intervertebral disc degeneration, and belongs to the technical field of medicines. The medicine comprises a midbrain astrocyte-derived neurotrophic factor or a reagent for overexpressing MANF, the reagent is a gene for expressing MANF, and the medicine further comprises a lentivirus vector for carrying the reagent for overexpressing MANF. Expression of MANF is evaluated by using human nucleus pulposus tissue and a rat intervertebral disc puncture model, in vitro, a simulated degeneration condition of acid treatment is adopted, and the MANF level in nucleus pulposus-derived mesenchymal stem cells is detected, the role of MANF in acidosis is explored by knocking down or overexpressing MANF, downstream target points are identified by using transcriptome sequencing, and the treatment potential of NP-MSCs overexpressing MANF is evaluated by using a rat puncture model. The application explores a new pathological mechanism that an acidic environment in an intervertebral disc influences the repair capacity of endogenous nucleus pulposus-derived mesenchymal stem cells, and further causes the progression of intervertebral disc degeneration, and reveals the protection role of MANF in intervertebral disc degeneration, thereby opening up a new idea for the treatment of intervertebral disc degeneration.

This invention discloses a myelin-inspired three-dimensional PEG-modified tetrahedral framework nucleic acid and its application in achieving long circulation and rapid renal clearance. Using a DNA tetrahedral framework as a programmable backbone, PEG units are periodically introduced onto each edge of the DNA tetrahedron. The PEG chains are used as active structural components rather than passive surface modifiers to construct a myelin-inspired three-dimensional topological PEG network coating structure. Without significantly increasing the size of small molecules, a dense steric barrier is formed, significantly reducing serum protein adsorption and nuclease degradation. Simultaneously, it efficiently crosses the glomerular filtration barrier, achieving a synergistic effect in mice with approximately a two-fold increase in blood circulation half-life and over 90% renal clearance within 4 hours. Furthermore, it exhibits good biocompatibility and in vivo safety, providing a novel, efficient, and safe nucleic acid drug delivery strategy for diseases related to the accumulation of target substances, such as hyperbiliary acidosis.

Embodiments can relate to compositions and methods for the treatment of hair loss, which can include treatment of alopecia. The compositions and methods relate to an oral supplement to oral minoxidil includes a SLC22A9 inducer, a HIF-alpha inducer, and / or an acidifying agent. Acidifying blood of a patient suffering from alopecia can cause mild acidosis which can up-regulate SLC22A9 and / or down-regulate AABC3. Inducing SLC22A9, inducing HIF-alpha, and / or acidifying blood of the patient can facilitate oral forms of minoxidil to enter hair follicles.